# (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Source: https://onco.cc/trials/nct05907954/  
OnCo record `nct05907954` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Darovasertib in melanoma and uveal melanoma, run by IDEAYA Biosciences, active and no longer recruiting.

## Summary

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma is a phase 2 interventional study registered as NCT05907954 by IDEAYA Biosciences, with 160 participants planned, started 2023-07-03 and due to reach its primary completion in 2027-04-30. Interventions recorded: Darovasertib. Conditions listed: Uveal Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05907954
- Phase: 2
- Setting: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
- Sponsor: IDEAYA Biosciences
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT05907954: https://clinicaltrials.gov/study/NCT05907954

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Darovasertib](https://onco.cc/drugs/darovasertib/)
- companies: [IDEAYA Biosciences](https://onco.cc/companies/ideaya-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct05907954.json